Carl Quintanilla, Jim Cramer and David Faber discuss the surge in stocks. Markets getting a boost from blowout results from Goldman Sachs and Moderna’s vaccine news. Goldman Sachs crushing earnings estimates its biggest outperformance in nearly a decade. Revenue was more than $3.5 billion higher than the street was expecting, fueled by strong results in its trading and investment banking divisions. On the coronavirus front, shares of Moderna skyrocketing after saying its vaccine produced a “robust” immune response, or neutralizing antibodies, in all of its 45 patients in its early stage human trial. Other stocks tied to reopening, American Airlines, United, Royal Caribbean all popped on the news. And Apple getting a boost, as Needham increases its price target for the tech giant to $450, from $350.
Squawk on the Street
Stocks Surge, Moderna Skyrockets, Goldman’s Blowout Quarter, Needham Ups Apple
Carl Quintanilla, Jim Cramer and David Faber discuss the surge in stocks. Markets getting a boost from blowout results from Goldman Sachs and Moderna’s vaccine news. Goldman Sachs crushing earnings estimates its biggest outperformance in nearly a decade. Revenue was more than $3.5 billion higher than the street was expecting, fueled by strong results in its trading and investment banking divisions. On the coronavirus front, shares of Moderna skyrocketing after saying its vaccine produced a “robust” immune response, or neutralizing antibodies, in all of its 45 patients in its early stage human trial. Other stocks tied to reopening, American Airlines, United, Royal Caribbean all popped on the news. And Apple getting a boost, as Needham increases its price target for the tech giant to $450, from $350.
- Broadcast on:
- 15 Jul 2020